Tissue Plasminogen Activator, Plasminogen Activator Inhibitor-1, and Tissue Plasminogen Activator/Plasminogen Activator Inhibitor-1 Complex as Risk Factors for the Development of a First Stroke
- 1 January 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 31 (1) , 26-32
- https://doi.org/10.1161/01.str.31.1.26
Abstract
Background and Purpose—Abnormalities in the fibrinolytic system have been associated with an increased risk for stroke in a few studies. This study was designed to test whether plasma levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), and tPA/PAI-1 complex could predict a first-ever stroke. Methods—The study was an incident case-control study nested within the Västerbotten Intervention Program and the Northern Sweden Monitoring Trends and Determinants in Cardiovascular Disease (MONICA) cohorts. In this study 108 first-ever stroke cases were defined according to the MONICA classification, and 216 controls from the same cohort were randomly selected and matched for age, sex, sampling time, and geographic region. Results—Stroke occurred on average 30 months after the blood sampling date. The mean plasma concentration of tPA/PAI-1 complex was higher for the stroke cases than for the controls (3.9 versus 3.0 μg/L). In univariate regression analysis, significantly higher o...Keywords
This publication has 27 references indexed in Scilit:
- Secular trends in social patterning of cardiovascular risk factor levels in Sweden. The Northern Sweden MONICA Study 1986–1994Journal of Internal Medicine, 1998
- Perceived health modifies the effect of biomedical risk factors in the prediction of acute myocardial infarction. An incident case–control study from northern SwedenJournal of Internal Medicine, 1998
- Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexesScandinavian Journal of Clinical and Laboratory Investigation, 1998
- Thrombogenic and Fibrinolytic Factors and Cardiovascular Risk in Non-insulin-dependent Diabetes MellitusAnnals of Medicine, 1996
- Prospective study of endogenous tissue plasminogen activator and risk of strokeThe Lancet, 1994
- Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart StudyThe Lancet, 1993
- Endogenous tissue-type plasminogen activator and risk of myocardial infarctionThe Lancet, 1993
- The world health organization monica project (monitoring trends and determinants in cardiovascular disease): A major international collaborationJournal of Clinical Epidemiology, 1988
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- In vivo metabolism of human tissue‐type plasminogen activatorScandinavian Journal of Haematology, 1984